Tango Therapeutics, Inc.

Tango Therapeutics announced promising updated results from its Phase 1/2 clinical trial evaluating vopimetostat in combination with RAS(ON) inhibitors. The combination of vopimetostat and daraxonrasib demonstrated an 82% objective response rate (ORR) and an 88% 9-month progression-free survival (PFS) rate in patients with second- or third-line MTAP-deleted/RAS-mutant pancreatic ductal adenocarcinoma (PDAC). The combination was generally well-tolerated at dose level 1. Based on these results and discussions with the FDA, Tango plans to initiate a registrational Phase 3 trial in front-line MTAP-deleted PDAC in the first half of 2027.

Tango Therapeutics, Inc. has expanded its at-the-market (ATM) equity offering program. The company previously had an ATM program for up to $100 million, under which it sold approximately $64.4 million in shares, leaving $35.6 million unsold. A new prospectus supplement has been filed to offer up to $400 million in common stock, which includes the remaining $35.6 million from the prior program. The previous $100 million program has been terminated.

Tango Therapeutics reported positive Phase 1/2 data for vopimetostat in combination with daraxonrasib, achieving a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted, RAS-mutant pancreatic cancer. The company plans to advance this combination into Phase 3 development and will present data at the 2026 ESMO Congress. For Q2 2026, Tango reported a net loss of $55.3 million, or $0.37 per share, and held $1.0 billion in cash. Additionally, Fatma Ocak was appointed Chief Commercialization Officer and Robert Azelby became Chairman of the Board.

Tango Therapeutics reported a net loss of $(100.9) million for the six months ended June 30, 2026, with no collaboration revenue. The company significantly strengthened its financial position by raising $651.4 million in net proceeds from an underwritten public offering in June 2026. As of June 30, 2026, its cash, cash equivalents, and marketable securities totaled $1.0 billion, providing a liquidity runway for at least the next 12 months.

Tango Therapeutics reported positive Phase 1/2 data for vopimetostat in combination with daraxonrasib for MTAP-deleted, RAS-mutant pancreatic cancer, showing a 92% objective response rate and 90% six-month progression-free survival. The company is preparing for late-stage clinical advancement and will present data at the 2026 ESMO Congress. Financially, Tango reported a Q2 2026 net loss of $55.3 million and held $1.0 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. Key appointments include Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board.

Tango Therapeutics, Inc. announced that Dr. Barbara Weber, the Executive Chairman of its Board of Directors, will be stepping down from her position. Dr. Weber is leaving to pursue other interests, expressing confidence in the company's accomplishments and future prospects. Tango Therapeutics acknowledged her significant contributions, including her vision, leadership, and dedication to the company's groundbreaking work.

Tango Therapeutics announced that Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, leading to her resignation from all officer and board positions. Her departure was not due to any disagreement with the company. In connection with her separation, Dr. Weber was offered a severance package including base salary through December 31, 2026, COBRA reimbursement, accelerated vesting of stock awards, and a pro-rata annual incentive.

Tango Therapeutics, a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings over three decades of biopharmaceutical industry leadership, including deep expertise in oncology commercialization and corporate strategy. His appointment is expected to be invaluable as Tango advances vopimetostat, its investigational PRMT5 inhibitor, towards potential late-stage development for pancreatic cancer.

Tango Therapeutics entered into an underwriting agreement for a public offering of 18,166,667 shares of common stock and 1,833,395 pre-funded warrants. The offering is expected to generate approximately $566.5 million in net proceeds. The company plans to use these funds for general corporate purposes, including research and development, pivotal trials, and potential commercialization, extending its cash runway into 2030.

Tango Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering expected to generate approximately $600 million in gross proceeds. The offering includes 18,166,667 shares of common stock priced at $30.00 per share and pre-funded warrants for up to 1,833,395 shares at $29.999 each. The company has also granted the underwriters a 30-day option to purchase an additional 3,000,009 shares of common stock.